H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) today and set a price target of $10.00. The company's shares closed last Wednesday at $1.45, close to its 52-week low of $1.31. According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -11.4% and a 28.3% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clearside Biomedical with a $9.67 average price target, implying a 515.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-clearside-biomedicals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral